Vitality Watch

Dossier pubmed review 24-jun-2026
Narrative review or expert overview without new data

Osteoarthritis as a Whole-Joint Disease, Part II: Emerging Nociceptive, Metabolic, Senescence, and Regenerative Therapeutic Targets, with Perspectives on Precision Care.

Key claim: Osteoarthritis care is expanding beyond joint-compartment structural targets to nociceptive pathways, systemic metabolic dysfunction and obesity, aging-associated cellular senescence, and regenerative intra-articular therapies, though consistent durable clinical success remains limited.

Abstract

This second part of the review builds on Part I, which focused on current standard-of-care management and structural therapeutic targets within the joint compartment, including cartilage, synovium, and subchondral bone. Here, we examine therapeutic strategies that extend beyond that axis, including peripheral and central pain pathways, systemic metabolic dysfunction and obesity, aging-associated cellular senescence, and contemporary regenerative intra-articular therapies such as platelet-rich plasma, hyaluronic acid, lubricin, and cell-based products. Although several of these approaches have shown encouraging mechanistic or symptomatic signals, consistent and durable clinical success has remained limited.

Why this matters

Osteoarthritis care is expanding beyond joint-compartment structural targets to nociceptive pathways, systemic metabolic dysfunction and obesity, aging-associated cellular senescence, and regenerative intra-articular therapies, though consistent durable clinical success remains limited.

Source

Link

Briefing card

Osteoarthritis as a Whole-Joint Disease, Part II: Emerging Nociceptive, Metabolic, Senescence, and Regenerative Therapeutic Targets, with Perspectives on Precision Care.
Stage: review · pubmed · 24-jun-2026

Osteoarthritis care is expanding beyond joint-compartment structural targets to nociceptive pathways, systemic metabolic dysfunction and obesity, aging-associated cellular senescence, and regenerative intra-articular therapies, though consistent durable clinical success remains limited.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.ocl.2026.05.002

build build 880 · 2bcef25 · 2026-11-18